Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Funding round brings in additional $3M for fibrotic disease drugmaker
Promedior, a developer of fibrotic disease treatments, raised an additional $3 million from Shire Strategic Investment Group in the second closing of a Series D financing round. The firm will use the proceeds to continue development of its experimental drugs, including its lead candidate, PRM-151, which is in early-stage clinical development for idiopathic pulmonary fibrosis.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .